Rothman KJ. A potential bias in safety evaluation during open-label extensions of randomized clinical trials. Pharmacoepidemiol Drug Saf. 2004 Jan 1;13(5):295-8.
Mosis G, Gutierrez LP, Dieleman J, Castellsague J, Sturkenboom M. No changes in channeling of COX-2 Specific inhibitors in the first three years after marketing. Poster presented at the ISoP Annual Conference ‘Pharmacovigilance in Clinical Practice’; October 2003. Marrakech, Morocco. [abstract] Pharmacoepidemiol Drug Saf. 2003 Oct; 12(S2):S243.
Arana A, Broeckmans AW. Validity of epidemiological research conducted following Good Clinical Practice Guidelines. Presented at the 19th International Conference on Pharmacoepidemiology; 2003.
Rothman KJ, Ray W. Should cases with a 'known' cause of their disease be excluded from study? (Commentary). Pharmacoepidemiol Drug Saf. 2002 Jan 1;11(1):11-4.
Rothman KJ, Ray W. Should epidemiologists exclude cases with a known cause of their disease? Pharmacoepidemiol Drug Saf. 2002;11:11-4.